NASDAQ: ACORAcorda Therapeutics Inc Stock
$0.60-0.05 (-7.69%)
Updated May 26, 2023
ACOR Price
$0.60
Fair Value Price
$2.55
Market Cap
$14.48M
52 Week Low
$0.26
52 Week High
$1.24
P/E
-0.22x
P/B
0.19x
P/S
0.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$118.29M
Earnings
-$58.22M
Gross Margin
76.7%
Operating Margin
0.31%
Profit Margin
-49.2%
Debt to Equity
3.87
Operating Cash Flow
-$14M
Beta
1.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACOR Overview
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACOR ($0.60) is undervalued by 76.71% relative to our estimate of its Fair Value price of $2.55 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACOR ($0.60) is significantly undervalued by 76.71% relative to our estimate of its Fair Value price of $2.55 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ACOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACOR due diligence checks available for Premium users.
Be the first to know about important ACOR news, forecast changes, insider trades & much more!
ACOR News
Valuation
ACOR fair value
Fair Value of ACOR stock based on Discounted Cash Flow (DCF)
Price
$0.60
Fair Value
$2.55
Undervalued by
76.51%
ACOR ($0.60) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACOR ($0.60) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACOR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
11.86x
Market
54.23x
ACOR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.19x
Industry
5.18x
ACOR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACOR's financial health
Profit margin
Revenue
$22.3M
Net Income
-$16.8M
Profit Margin
-75.6%
ACOR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ACOR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$374.9M
Liabilities
$297.9M
Debt to equity
3.87
ACOR's short-term assets ($68.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACOR's long-term liabilities ($263.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACOR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.0M
Investing
$0.0
Financing
$0.0
ACOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACOR vs Biotech Stocks
Acorda Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.